Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.

IF 2.1 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2026-03-09 DOI:10.1080/1120009X.2026.2640329

Zi Wang, Yan Zhang, Danqing Zhao, Chong Wei, Wei Wang, Daobin Zhou, Wei Zhang

{"title":"Analysis of risk factors for infusion-related reactions in patients with B-cell lymphoma during obinutuzumab treatment.","authors":"Zi Wang, Yan Zhang, Danqing Zhao, Chong Wei, Wei Wang, Daobin Zhou, Wei Zhang","doi":"10.1080/1120009X.2026.2640329","DOIUrl":null,"url":null,"abstract":"This study investigated the risk factors associated with infusion-related reactions (IRRs) in B-cell lymphoma patients receiving obinutuzumab. A retrospective analysis of Peking Union Medical College Hospital patients (January 2021-December 2024) was conducted to examine factors between patients experiencing IRRs (n = 44) and those without (n = 56). Parameters included gender, age, histological subtype, treatment status, Ann Arbor staging, extranodal/bone marrow involvement, bulky disease, splenomegaly status, serum lactate dehydrogenase (LDH), beta-2 microglobulin (β2MG) concentrations, and lymphocyte count. 100 patients (48 men, 52 women) with a mean age of 55.7 years (range: 44-67) received obinutuzumab. Univariate analyses showed higher prevalence of bone marrow involvement and splenomegaly in the IRR group. Median LDH (235 vs. 195) and β2MG (4 vs. 3) levels pre-treatment were significantly elevated in the IRR group (P < 0.05). Multivariate analysis identified splenomegaly and pre-treatment LDH levels as IRR risk factors. This research assists in predicting IRRs to improve patient outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2026.2640329","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

This study investigated the risk factors associated with infusion-related reactions (IRRs) in B-cell lymphoma patients receiving obinutuzumab. A retrospective analysis of Peking Union Medical College Hospital patients (January 2021-December 2024) was conducted to examine factors between patients experiencing IRRs (n = 44) and those without (n = 56). Parameters included gender, age, histological subtype, treatment status, Ann Arbor staging, extranodal/bone marrow involvement, bulky disease, splenomegaly status, serum lactate dehydrogenase (LDH), beta-2 microglobulin (β₂MG) concentrations, and lymphocyte count. 100 patients (48 men, 52 women) with a mean age of 55.7 years (range: 44-67) received obinutuzumab. Univariate analyses showed higher prevalence of bone marrow involvement and splenomegaly in the IRR group. Median LDH (235 vs. 195) and β₂MG (4 vs. 3) levels pre-treatment were significantly elevated in the IRR group (P < 0.05). Multivariate analysis identified splenomegaly and pre-treatment LDH levels as IRR risk factors. This research assists in predicting IRRs to improve patient outcomes.

查看原文本刊更多论文

b细胞淋巴瘤患者输注相关反应的危险因素分析

本研究探讨了接受本品治疗的b细胞淋巴瘤患者输注相关反应（IRRs）的相关危险因素。回顾性分析北京协和医院2021年1月至2024年12月的患者，探讨发生IRRs的患者（n = 44）与未发生IRRs的患者（n = 56）之间的影响因素。参数包括性别、年龄、组织学亚型、治疗状况、安娜堡分期、结外/骨髓累及、肿大疾病、脾肿大状况、血清乳酸脱氢酶（LDH）、β -2微球蛋白（β2MG）浓度和淋巴细胞计数。100名患者（48名男性，52名女性）平均年龄55.7岁（范围：44-67岁）接受了obinutuzumab治疗。单因素分析显示，IRR组骨髓受累和脾肿大的发生率较高。IRR组治疗前LDH中位数（235比195）和β2MG中位数（4比3）水平显著升高(P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.